cancer immunotherapy

Researchers investigated how cancer antigenicity drives unique forms of T cell exhaustion and hypofunctionality.

The Scientist spoke with Jonathan Kagan about his idea that immune cells respond to “errors” made by unsuccessful pathogens, not the pathogens themselves.

The extent to which transcription is higher in tumor cells than in surrounding nontumor cells is associated with bad prognoses in several cancer types.

A study finds that engineered exosomes are effective in mice, but their potential use in humans raises safety questions.  

Dormant cancer cells and dysfunctional immune cells living together in a tumor niche form a therapy-resistant reservoir.

Nanoparticle-coated bacteria can capture tumor antigens and deliver them to immune cells, triggering a response that improved survival rates in mice.

Nanoparticle-coated bacteria carry cancer-derived proteins to dendritic cells, enabling the immune system to launch a response in a mouse model.

Because most people are vaccinated against tetanus as children, delivering benign bacteria carrying a tetanus antigen into pancreatic tumors makes them visible to memory cells in the immune system, researchers report.

When coated with positively charged particles, the bacteria shuttled antigens out of tumors and activated the immune system, a study finds.

Specialized immune cells generated in vivo reduce cardiac scar tissue in mice, a new study shows.

Several research groups have found that Toxoplasma gondii infection can ramp up antitumor immune responses in mice. Can the single-cell parasite be used to develop safe treatments for humans?

The binding of histamine with one of its receptors within the tumor environment makes cancer cells more resistant to immunotherapy, according to a new study. Blocking that binding could improve responses to treatment.

A career-altering experience as a cancer patient motivated one researcher to design more potent immunotherapies.